Stock Analysis
Omda (OB:OMDA) Full Year 2023 Results
Key Financial Results
- Revenue: kr415.1m (up 12% from FY 2022).
- Net income: kr104.4m (up from kr131.6m loss in FY 2022).
- Profit margin: 25% (up from net loss in FY 2022). The move to profitability was primarily driven by lower expenses.
- EPS: kr5.11 (up from kr6.28 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Omda EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.6%.
Looking ahead, revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
Performance of the market in Norway.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Be aware that Omda is showing 5 warning signs in our investment analysis and 4 of those don't sit too well with us...
Valuation is complex, but we're helping make it simple.
Find out whether Omda is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OB:OMDA
Omda
Provides software solutions for healthcare sector in Norway, Sweden, Denmark, and internationally.